ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: Repligen Corporation (RGEN) Report Updated: Oct 27, 2014 | Print This Page

Get more stock ratings by Louis Navellier

Repligen Corporation (RGEN)

Rating: Strong Buy Volatility: Moderate
Total Grade: A Industry: Biotechnology
Competitors: UTHR, ACHN, CMRX, RNA

Stock Analysis

Rating: Monthly View

A
B
C
D
F
October November December January February March April May June July August September

Rating: Weekly View

This Week: A down no change
Last Week: A same no change
Two Weeks Ago: A up no change
service keys

Repligen Corporation© quotemedia

Company Profile

Repligen Corporation engages in the manufacture and supply of biologic products used to manufacture biologic drugs. The company offers commercial bioprocessing products based on protein A and IFG-1 growth factors; and pre-packed chromatography columns under the Opus brand, which are used in the production of monoclonal antibodies and other biopharmaceutical products. It also develops SecreFlo, a synthetic human hormone that has completed a Phase III clinical trial and is to be used in combination with magnetic resonance imaging to improve the detection of pancreatic abnormalities in patients with pancreatitis; RG3039, which is in Phase I study for the treatment of patients with spinal muscular atrophy; and RG2833, a class I histone deacetylase inhibitor that is in Phase I study for the treatment of patients with Friedreich’s ataxia. In addition, the company licenses its biologics intellectual property to Bristol-Myers Squibb Company. Repligen Corporation sells its bioprocessing products to life science companies, diagnostics companies, biopharmaceutical companies, and laboratory researchers through its direct sales force, partners, and distributors in certain foreign markets. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.

Recent News: Repligen Corporation